Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Kairos Pharma, Ltd.. The associated price target remains the same with $4.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors related to Kairos Pharma’s promising drug development pipeline and upcoming catalysts. The company’s lead candidate, ENV-105, is designed to target CD105, a protein involved in tumor resistance, with the aim of enhancing the effectiveness of existing cancer therapies. This innovative approach has shown potential in early trials, particularly in metastatic castration-resistant prostate cancer (mCRPC) where ENV-105 is being tested in combination with Erleada.
The anticipation of interim efficacy data from the Phase 2 trial in September is a significant potential catalyst for the stock. Additionally, the ongoing Phase 1 study of ENV-105 in combination with Tagrisso for EGFR-mutated non-small cell lung cancer (NSCLC) also presents a promising opportunity, with initial data expected by the end of the year. These developments, along with the company’s financial position, which is expected to support operations into 2026, contribute to McCarthy’s optimistic outlook on Kairos Pharma.
McCarthy covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.3% and a 26.76% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.